Playing the Melanoma Endgame.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 29769205.
- Also identified by DOI 10.1158/1078-0432.CCR-18-0989 and PMC identifier 6168356.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Treatments for melanoma are of two main types: targeted therapies and immune checkpoint inhibitors. However, both are effective in only a subset of patients and are limited by acquired resistance. Here, the authors present the preclinical basis to broadly target different forms of therapy-resistant melanoma. <i>Clin Cancer Res; 24(19); 4629-30. ©2018 AACR</i> <i>See related article by Zhang et al., p. 4771</i>.
Medical subject headings
- Melanoma
- Telomere